Source comparison
Semax-Adamantyl vs Standard Semax: Research Application Comparison
Plasma Half-Life 20–30 minutes 4–6 hours Adamantyl modification provides 8–12× extension, reducing dosing frequency Blood-Brain Barrier Penetration Low (logP −2.1, hydrophilic) Moderate (logP −0.4, enhanced lipophilicity) 2–3× higher CSF concentrations at equi
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- 20–30 minutes
- 4–6 hours
- Adamantyl modification provides 8–12× extension, reducing dosing frequency
- Blood-Brain Barrier Penetration
- Low (logP −2.1, hydrophilic)
- Moderate (logP −0.4, enhanced lipophilicity)
- 2–3× higher CSF concentrations at equivalent doses
- Dosing Frequency for Sustained Effect
- 3–4× daily
- 1–2× daily
- Critical advantage in chronic models and multi-week protocols
- Receptor Selectivity
- MC4R, MC5R
- MC4R, MC5R (unchanged)
- No alteration to binding profile. Modification is purely pharmacokinetic
- Enzymatic Stability
- Rapidly degraded by aminopeptidases
- Steric hindrance delays prolyl endopeptidase cleavage
- Extends therapeutic window without altering mechanism
- Optimal Research Applications
- Acute neuroprotection, immediate cognitive response
- Chronic neuroplasticity, sustained BDNF modulation, long-term potentiation studies
- Choose based on experimental timeline and dosing constraints